<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00049439</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU2498</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CWRU-029828J</secondary_id>
    <secondary_id>CWRU-2498</secondary_id>
    <secondary_id>NCI-G02-2126</secondary_id>
    <secondary_id>CASE-2498</secondary_id>
    <nct_id>NCT00049439</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Dose-Modified Oral Combination Chemotherapy In Patients With Aids-Related Non-Hodgkin's Lymphoma In The United States And Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining more than one drug may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining lomustine, etoposide,&#xD;
      cyclophosphamide, and procarbazine in treating patients who have AIDS-related non-Hodgkin's&#xD;
      lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the objective response rate, response duration, and survival of patients with&#xD;
           AIDS-related non-Hodgkin's lymphoma treated with lomustine, etoposide, cyclophosphamide,&#xD;
           and procarbazine.&#xD;
&#xD;
        -  Determine the feasibility of this regimen in these patients.&#xD;
&#xD;
        -  Determine the clinical toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Assess the quality of life of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the impact of this regimen on the underlying HIV infection in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral lomustine on day 1 (course 1 only), oral etoposide on days 1-3, and&#xD;
      oral cyclophosphamide and oral procarbazine on days 22-26. Patients may also receive&#xD;
      filgrastim (G-CSF) subcutaneously on days 5-21 and 28-42. Treatment repeats every 6 weeks for&#xD;
      2 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, on days 1 and 22 of each course, at day 84, and then&#xD;
      every 3 months for 1 year.&#xD;
&#xD;
      Patients are followed at day 84 and then every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 66 patients (22 in the United States and 44 in Africa) will be&#xD;
      accrued for this study within 3-4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1998</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease response</measure>
    <time_frame>Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed by the Functional Living Index-Cancer and the Brief Symptom Inventory</measure>
    <time_frame>days 1 and 2 of courses 1 and 2 and on day 84</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">54</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>filgrastim (G-CSF) subcutaneously on days 5-21 and 28-42. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Oral cyclophosphamide on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Oral etoposide on days 1-3. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lomustine</intervention_name>
    <description>Oral lomustine on day 1 (course 1 only). Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>procarbazine hydrochloride</intervention_name>
    <description>Oral procarbazine on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of acquired immune deficiency syndrome&#xD;
&#xD;
          -  Histologically confirmed stage I, II, III, or IV intermediate- or high-grade&#xD;
             non-Hodgkin's lymphoma&#xD;
&#xD;
               -  B-cell, T-cell, or indeterminate immunologic phenotype&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No clinical, radiographic, or cytological evidence of CNS parenchymal, vitreal, or&#xD;
             leptomeningeal involvement by lymphoma NOTE: A new classification scheme for adult&#xD;
             non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of &quot;indolent&quot; or&#xD;
             &quot;aggressive&quot; lymphoma will replace the former terminology of &quot;low&quot;, &quot;intermediate&quot;, or&#xD;
             &quot;high&quot; grade lymphoma. However, this protocol uses the former terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over (in the United States)&#xD;
&#xD;
          -  16 and over (in Africa)&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-3&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 6 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 50,000/mm3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 3.0 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 3.0 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Concurrent active infection for which patient is receiving treatment allowed provided&#xD;
             clinical status is stable&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for lymphoma&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Prior radiotherapy for stage I or II disease allowed provided there is documentation&#xD;
             of disease progression&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Concurrent antiretroviral therapy (except zidovudine) allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scot C. Remick, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nairobi College of Health Sciences</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uganda Cancer Institute</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>Uganda</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>November 12, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 9, 2010</last_update_submitted>
  <last_update_submitted_qc>June 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Scot Remick, MD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensvie Cancer Center</organization>
  </responsible_party>
  <keyword>AIDS-related diffuse large cell lymphoma</keyword>
  <keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
  <keyword>AIDS-related diffuse small cleaved cell lymphoma</keyword>
  <keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
  <keyword>AIDS-related lymphoblastic lymphoma</keyword>
  <keyword>AIDS-related small noncleaved cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Lomustine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

